Transfusion associated graft versus host disease following whole blood transfusion: an unusual case of expanded dengue syndrome
DOI:
https://doi.org/10.18203/2349-3933.ijam20250379Keywords:
Transfusion associated GVHD, Thrombocytopenia, Blood transfusion, Expanded dengue syndromeAbstract
Dengue infection presents in a diverse array of manifestations, including dengue fever (DF), dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). To include cases that do not fit the criteria for either DHF or DSS and show atypical manifestations across multiple organ systems, world health organization (WHO) coined the term expanded dengue syndrome (EDS). A 47-yr-old female presented with fever, chills, blanchable rash, itching and burning sensation all over body with skin peeling over the last 5 days. In the outside hospital, she developed melena and thrombocytopenia, for which she received 1unit packed red blood cells, 1 unit of single donor platelets from her brother. After 1 week she developed above symptoms and was referred to us for pancytopenia. On evaluation her platelets, leucocyte count was low with normal Hb levels. The bone marrow biopsy revealed a hypoplastic marrow accompanied by significant proliferation of pre-progenitor megakaryocytes. She had mild transaminitis, without hyperbilirubinemias. Blood culture grew candida spp, Enterococcus faecium. She received appropriate antibiotics along G-CSF. Skin biopsy revealed basal vacuolation, spongiosis in epidermis, necrotic epidermis, apoptotic keratinocytes scattered in intact epidermis suggestive of acute GVHD Gr-Ⅲ. Consequently, she was commenced on pulsed steroid regimen followed by maintenance dose. Within a week, her clinical condition improved and was discharged on tapering dose of steroids. The existence of donor-derived cells or DNA in the recipient's blood or afflicted tissues must be documented to make conclusive diagnosis of TA-GVHD.
Metrics
References
Murray NE, Quam MB, Wilder-Smith A. Epidemiology of dengue: past, present and future prospects. Clin Epidemiol. 2013;5:299-309. DOI: https://doi.org/10.2147/CLEP.S34440
Khetarpal N, Khanna I. Dengue Fever: Causes, Complications, and Vaccine Strategies. J Immunol Res. 2016;2:6803098. DOI: https://doi.org/10.1155/2016/6803098
Whitehorn J, Farrar J. Dengue. Br Med Bull. 2010;95:161-73. DOI: https://doi.org/10.1093/bmb/ldq019
Umakanth M, Suganthan N. Unusual Manifestations of Dengue Fever: A Review on Expanded Dengue Syndrome. Cureus. 2020;12(9):10678. DOI: https://doi.org/10.7759/cureus.10678
Gulati S, Maheshwari A. Atypical manifestations of dengue. Trop Med Int Health. 2007;12(9):1087-95. DOI: https://doi.org/10.1111/j.1365-3156.2007.01891.x
Brubaker D. Transfusion-associated graft-versus-host disease. Human Pathol. 1986;17(11):1085-8. DOI: https://doi.org/10.1016/S0046-8177(86)80412-9
Kadam DB, Salvi S, Chandanwale A. Expanded Dengue. J Assoc Physicians India. 2016;64(7):59-63.
Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition. Geneva: World Health Organization. 2009.
Krishnamurti C, Peat RA, Cutting MA, Rothwell SW. Platelet adhesion to dengue-2 virus-infected endothelial cells. Am J Trop Med Hyg. 2002;66(4):435-41. DOI: https://doi.org/10.4269/ajtmh.2002.66.435
Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med. 2006;354(19):2034-45. DOI: https://doi.org/10.1056/NEJMra052706
Uchida S, Tadokoro K, Takahashi M, Yahagi H, Satake M, Juji T. Analysis of 66 patients definitive with transfusion-associated graft-versus-host disease and the effect of universal irradiation of blood. Transfus Med. 2013;23(6):416-22. DOI: https://doi.org/10.1111/tme.12081
Rühl H, Bein G, Sachs UJ. Transfusion-associated graft-versus-host disease. Transfus Med Rev. 2009;23(1):62-71. DOI: https://doi.org/10.1016/j.tmrv.2008.09.006
Shivdasani RA, Haluska FG, Dock NL, Dover JS, Kineke EJ, Anderson KC. Brief report: graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med. 1993;328(11):766-70. DOI: https://doi.org/10.1056/NEJM199303183281105
Thaler M, Shamiss A, Orgad S, Huszar M, Nussinovitch N, Meisel S, et al. The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery. N Engl J Med. 1989;321(1):25-8. DOI: https://doi.org/10.1056/NEJM198907063210105
Vogelsang GB. Transfusion-associated graft-versus-host disease in no immunocompromised hosts. Transfusion. 1990;30(2):101-3. DOI: https://doi.org/10.1046/j.1537-2995.1990.30290162892.x
Patel KK, Patel AK, Ranjan RR, Shah AP. Transfusion associated graft versus host disease following whole blood transfusion from an unrelated donor in an immunocompetent patient. Indian J Hematol Blood Transfus. 2010;26(3):92-5. DOI: https://doi.org/10.1007/s12288-010-0028-0
Matsukuma KE, Wei D, Sun K, Ramsamooj R, Chen M. Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD). J Gastrointest Oncol. 2016;7(1):21-31.
ALZahrani D, ALShamrani M, Kassar A, ALThubaiti S, ALGamdi K, Guler M, et al. Transfusion-associated graft-versus-host disease confirmed by human leukocyte antigen typing in a patient with severe combined immunodeficiency and review of the literature. J Clin Rev & Case Reports. 2000;5(1):46-51.
Gupta A. Graft versus host disease associated with blood transfusion. Trends Transplant. 2017;2:78. DOI: https://doi.org/10.15761/TiT.1000225
Hutchinson K, Kopko PM, Muto KN, Tuscano J, O'Donnell RT, Holland PV, et al. Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplant. Transfusion 2002;42(12):1567–72. DOI: https://doi.org/10.1046/j.1537-2995.2002.00253.x
Ryo R, Saigo K, Hashimoto M, Kohsaki M, Yasufuku M, Watanabe N, et al. Treatment of posttransfusion graft-versus-host disease with nafmostat mesilate, a serine protease inhibitor. Vox Sang. 1999;76(4):241–6. DOI: https://doi.org/10.1046/j.1423-0410.1999.7640241.x
Downloads
Published
How to Cite
Issue
Section
